Vernalis (R&D) Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vernalis (R&D) Ltd.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
- Other Names / Subsidiaries
- Cita NeuroPharmaceuticals
- Vernalis Group plc
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.